trimetrexate has been researched along with Stomach Neoplasms in 4 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Stomach Neoplasms: Tumors or cancer of the STOMACH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 9.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression." | 5.14 | S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010) |
| "Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8-12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days." | 5.07 | Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study. ( Hantel, A; Macdonald, JS; Pollock, T; Pugh, RP; Richman, SP; Tangen, CM, 1994) |
| " The dosage of TMTX was reduced to 8 mg/m(2) daily for 5 days for those who had received prior radiotherapy." | 2.69 | Phase II trial of trimetrexate for patients with advanced gastric carcinoma: an Eastern Cooperative Oncology Group study (E1287). ( Asbury, RF; Greenberg, BR; Haller, DG; Lipsitz, S; Qazi, R; Ramanathan, RK, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanke, CD | 1 |
| Chansky, K | 1 |
| Christman, KL | 1 |
| Hundahl, SA | 1 |
| Issell, BF | 1 |
| Van Veldhuizen, PJ | 1 |
| Budd, GT | 1 |
| Abbruzzese, JL | 1 |
| Macdonald, JS | 2 |
| Hantel, A | 1 |
| Tangen, CM | 1 |
| Richman, SP | 1 |
| Pugh, RP | 1 |
| Pollock, T | 1 |
| Haller, DG | 2 |
| Ramanathan, RK | 1 |
| Lipsitz, S | 1 |
| Asbury, RF | 1 |
| Qazi, R | 1 |
| Greenberg, BR | 1 |
1 review available for trimetrexate and Stomach Neoplasms
| Article | Year |
|---|---|
Trimetrexate: experience with solid tumors.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a | 1997 |
3 trials available for trimetrexate and Stomach Neoplasms
| Article | Year |
|---|---|
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2010 |
Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Aged; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Trimetrexate | 1994 |
Phase II trial of trimetrexate for patients with advanced gastric carcinoma: an Eastern Cooperative Oncology Group study (E1287).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Disease Progression; Femal | 1999 |